Tech Company Financing Transactions
Biodesix Funding Round
Biodesix closed a $11 million Series E financing round on 6/24/2015. Investors included private investors.
Transaction Overview
Company Name
Announced On
6/24/2015
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series E
Investors
Proceeds Purpose
The investment will be used for ongoing new product development and expansion of commercial efforts to support Biodesix' commercialized products, VeriStrat and GeneStrat, as well as new product launches in 2015 -- 2016.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
2970 Wilderness Pl. 100
Boulder, CO 80301
USA
Boulder, CO 80301
USA
Phone
Website
Email Address
Overview
Biodesix (Nasdaq: BDSX) makes blood-based diagnostic tests that help guide treatment of patients with advanced cancer. Our test results are available within 72 hours.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Brunel
Chief Financial Officer
Robin Cowie
Chief Marketing Officer
Bobbi Coffin
Chief Scientific Officer
Linda Traylor
Chief Technical Officer
Heinrich Röder
VP - Bus. Development
Paul Beresford
VP - Human Resources
James Purvis
VP - Operations
Gary Pestano
Browse more venture capital transactions:
Prev: 6/24/2015: Diib venture capital transaction
Next: 6/24/2015: Tanvas venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs